These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 18075294)

  • 1. Somatostatin receptor scintigraphy in thoracic diseases.
    Ameri P; Gatto F; Arvigo M; Villa G; Resmini E; Minuto F; Murialdo G; Ferone D
    J Endocrinol Invest; 2007 Nov; 30(10):889-902. PubMed ID: 18075294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
    Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
    Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
    Oberg K; Eriksson B
    Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor SPECT.
    Pepe G; Moncayo R; Bombardieri E; Chiti A
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S41-51. PubMed ID: 22388628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
    Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
    Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide receptor imaging and therapy.
    Kwekkeboom D; Krenning EP; de Jong M
    J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.
    Chua S; Gnanasegaran G; Cook GJ
    Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
    Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
    Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings.
    Kuyumcu S; Adalet I; Sanli Y; Turkmen C; Ozkan ZG; Yilmazbayhan D
    Ann Nucl Med; 2012 Nov; 26(9):689-97. PubMed ID: 22802007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
    Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
    Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial staging of lymphoma with octreotide and other receptor imaging agents.
    Ferone D; Semino C; Boschetti M; Cascini GL; Minuto F; Lastoria S
    Semin Nucl Med; 2005 Jul; 35(3):176-85. PubMed ID: 16098291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potentially misleading finding at somatostatin receptor scintigraphy: focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions.
    Minutoli F; Herberg A; Sindoni A; Cardile D; Cucinotta M; Baldari S
    J Endocrinol Invest; 2012 Jul; 35(7):708-9. PubMed ID: 22932274
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D; Mikołajczak R; Kamiński G
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study.
    Reisinger I; Bohuslavitzki KH; Brenner W; Braune S; Dittrich I; Geide A; Kettner B; Otto HJ; Schmidt S; Munz DL
    J Nucl Med; 1998 Feb; 39(2):224-7. PubMed ID: 9476922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
    Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
    J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visualization of gallbladder with In-111 labeled octreotide in post prandial state.
    Gedik GK; Kiratli PO; Erbas B
    Ann Nucl Med; 2006 Oct; 20(8):557-60. PubMed ID: 17134024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of neuroendocrine tumors.
    Rufini V; Calcagni ML; Baum RP
    Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide imaging with somatostatin analogues: more than cancer probes.
    Cascini GL; Cuccurullo V; Tamburrini O; Rotondo A; Mansi L
    Curr Radiopharm; 2013 Mar; 6(1):36-40. PubMed ID: 23470033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.